New biomolecular aspects in ischemic heart disease

Maurizio Coronelli, Sara Bozzinì, Angela D'Angelo, Maurizio Framarin, Colomba Falcone

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Several risk factors are known to promote atherosclerosis, and a number of biomarkers have been shown to identify patients at risk for coronary artery disease (CAD). Atherogenesis begins as a qualitative change to intact endothelial cells: when the endothelial cells are subjected to oxidative stress, hemodynamic forces, or biochemical stimuli and inflammatory factors, they allow the entry and retention of monocytes and cholesterol-containing LDL particles. One of the major subsets of mediators in the interaction between inflammatory cells and endothelial and smooth muscle cells and the subsequent perpetuation of the inflammatory reaction are cytokines, especially the interleukins, and macrophage-associated cytokines like tumor necrosis factor (TNF)-a and interferon (IFN)-y. Advances in understanding of the pathobioIogy of atherosclerosis have implicated inflammation as a central contributor to its initiation and progression.C-reactive protein (CRP) is the best studied of the inflammatory biomarkers in CAD and increasing evidence suggests the localization of CRP in the atherosclerotic plaque and its involvement in inflammatory process of atherosclerosis. An interesting novel biomarkers that has been extensively studied recently is soluble RAGE: its serum levels correlate positively with occurrence and severity of CAD, underlining their central role in the Pathogenesis of atherosclerosis. In recent years, many genes have been extensively explored, strong evidence of a molecular genetic association with coronary artery disease (CAD) or myocardial. In particular, in genome-wide study many loci were found to be associated with CAD. Finally, the most recent evidencesshows that miRNAs in a stable form can be detected in serum and in plasma and that they may be useful as biomarkers for CAD. However, the influence of endothelial activation and atherosclerotic disease, and that of current vasculoprotective therapy, on levels of circulating miRNAs is still unknown.The aim of the present review was to systematically report current evidence on the promising new biomarkers recently found to be associated with coronary artery disease and to evaluate their possible role in risk assessment. Drugs that inhibit inflammatory pathways are the subject of current research, but successful adoption of immunosuppressive drugs, means finding safe and effective compounds capable of directly suppressing plaque inflammation.

Original languageEnglish
Title of host publicationNew Developments in Myocardial Ischemia Research
PublisherNova Science Publishers, Inc.
Pages135-152
Number of pages18
ISBN (Print)9781634828550, 9781634828024
Publication statusPublished - Jan 1 2015

Fingerprint

Myocardial Ischemia
Coronary Artery Disease
Atherosclerosis
Biomarkers
Endothelial Cells
MicroRNAs
C-Reactive Protein
Cytokines
Inflammation
Interleukins
Atherosclerotic Plaques
Immunosuppressive Agents
Serum
Pharmaceutical Preparations
LDL Cholesterol
Interferons
Smooth Muscle Myocytes
Molecular Biology
Monocytes
Oxidative Stress

Keywords

  • Atherosclerosis
  • Biomarkers
  • Coronary artery disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Coronelli, M., Bozzinì, S., D'Angelo, A., Framarin, M., & Falcone, C. (2015). New biomolecular aspects in ischemic heart disease. In New Developments in Myocardial Ischemia Research (pp. 135-152). Nova Science Publishers, Inc..

New biomolecular aspects in ischemic heart disease. / Coronelli, Maurizio; Bozzinì, Sara; D'Angelo, Angela; Framarin, Maurizio; Falcone, Colomba.

New Developments in Myocardial Ischemia Research. Nova Science Publishers, Inc., 2015. p. 135-152.

Research output: Chapter in Book/Report/Conference proceedingChapter

Coronelli, M, Bozzinì, S, D'Angelo, A, Framarin, M & Falcone, C 2015, New biomolecular aspects in ischemic heart disease. in New Developments in Myocardial Ischemia Research. Nova Science Publishers, Inc., pp. 135-152.
Coronelli M, Bozzinì S, D'Angelo A, Framarin M, Falcone C. New biomolecular aspects in ischemic heart disease. In New Developments in Myocardial Ischemia Research. Nova Science Publishers, Inc. 2015. p. 135-152
Coronelli, Maurizio ; Bozzinì, Sara ; D'Angelo, Angela ; Framarin, Maurizio ; Falcone, Colomba. / New biomolecular aspects in ischemic heart disease. New Developments in Myocardial Ischemia Research. Nova Science Publishers, Inc., 2015. pp. 135-152
@inbook{772f8c25d4a04baf95954a843e0c1787,
title = "New biomolecular aspects in ischemic heart disease",
abstract = "Several risk factors are known to promote atherosclerosis, and a number of biomarkers have been shown to identify patients at risk for coronary artery disease (CAD). Atherogenesis begins as a qualitative change to intact endothelial cells: when the endothelial cells are subjected to oxidative stress, hemodynamic forces, or biochemical stimuli and inflammatory factors, they allow the entry and retention of monocytes and cholesterol-containing LDL particles. One of the major subsets of mediators in the interaction between inflammatory cells and endothelial and smooth muscle cells and the subsequent perpetuation of the inflammatory reaction are cytokines, especially the interleukins, and macrophage-associated cytokines like tumor necrosis factor (TNF)-a and interferon (IFN)-y. Advances in understanding of the pathobioIogy of atherosclerosis have implicated inflammation as a central contributor to its initiation and progression.C-reactive protein (CRP) is the best studied of the inflammatory biomarkers in CAD and increasing evidence suggests the localization of CRP in the atherosclerotic plaque and its involvement in inflammatory process of atherosclerosis. An interesting novel biomarkers that has been extensively studied recently is soluble RAGE: its serum levels correlate positively with occurrence and severity of CAD, underlining their central role in the Pathogenesis of atherosclerosis. In recent years, many genes have been extensively explored, strong evidence of a molecular genetic association with coronary artery disease (CAD) or myocardial. In particular, in genome-wide study many loci were found to be associated with CAD. Finally, the most recent evidencesshows that miRNAs in a stable form can be detected in serum and in plasma and that they may be useful as biomarkers for CAD. However, the influence of endothelial activation and atherosclerotic disease, and that of current vasculoprotective therapy, on levels of circulating miRNAs is still unknown.The aim of the present review was to systematically report current evidence on the promising new biomarkers recently found to be associated with coronary artery disease and to evaluate their possible role in risk assessment. Drugs that inhibit inflammatory pathways are the subject of current research, but successful adoption of immunosuppressive drugs, means finding safe and effective compounds capable of directly suppressing plaque inflammation.",
keywords = "Atherosclerosis, Biomarkers, Coronary artery disease",
author = "Maurizio Coronelli and Sara Bozzin{\`i} and Angela D'Angelo and Maurizio Framarin and Colomba Falcone",
year = "2015",
month = "1",
day = "1",
language = "English",
isbn = "9781634828550",
pages = "135--152",
booktitle = "New Developments in Myocardial Ischemia Research",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - New biomolecular aspects in ischemic heart disease

AU - Coronelli, Maurizio

AU - Bozzinì, Sara

AU - D'Angelo, Angela

AU - Framarin, Maurizio

AU - Falcone, Colomba

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Several risk factors are known to promote atherosclerosis, and a number of biomarkers have been shown to identify patients at risk for coronary artery disease (CAD). Atherogenesis begins as a qualitative change to intact endothelial cells: when the endothelial cells are subjected to oxidative stress, hemodynamic forces, or biochemical stimuli and inflammatory factors, they allow the entry and retention of monocytes and cholesterol-containing LDL particles. One of the major subsets of mediators in the interaction between inflammatory cells and endothelial and smooth muscle cells and the subsequent perpetuation of the inflammatory reaction are cytokines, especially the interleukins, and macrophage-associated cytokines like tumor necrosis factor (TNF)-a and interferon (IFN)-y. Advances in understanding of the pathobioIogy of atherosclerosis have implicated inflammation as a central contributor to its initiation and progression.C-reactive protein (CRP) is the best studied of the inflammatory biomarkers in CAD and increasing evidence suggests the localization of CRP in the atherosclerotic plaque and its involvement in inflammatory process of atherosclerosis. An interesting novel biomarkers that has been extensively studied recently is soluble RAGE: its serum levels correlate positively with occurrence and severity of CAD, underlining their central role in the Pathogenesis of atherosclerosis. In recent years, many genes have been extensively explored, strong evidence of a molecular genetic association with coronary artery disease (CAD) or myocardial. In particular, in genome-wide study many loci were found to be associated with CAD. Finally, the most recent evidencesshows that miRNAs in a stable form can be detected in serum and in plasma and that they may be useful as biomarkers for CAD. However, the influence of endothelial activation and atherosclerotic disease, and that of current vasculoprotective therapy, on levels of circulating miRNAs is still unknown.The aim of the present review was to systematically report current evidence on the promising new biomarkers recently found to be associated with coronary artery disease and to evaluate their possible role in risk assessment. Drugs that inhibit inflammatory pathways are the subject of current research, but successful adoption of immunosuppressive drugs, means finding safe and effective compounds capable of directly suppressing plaque inflammation.

AB - Several risk factors are known to promote atherosclerosis, and a number of biomarkers have been shown to identify patients at risk for coronary artery disease (CAD). Atherogenesis begins as a qualitative change to intact endothelial cells: when the endothelial cells are subjected to oxidative stress, hemodynamic forces, or biochemical stimuli and inflammatory factors, they allow the entry and retention of monocytes and cholesterol-containing LDL particles. One of the major subsets of mediators in the interaction between inflammatory cells and endothelial and smooth muscle cells and the subsequent perpetuation of the inflammatory reaction are cytokines, especially the interleukins, and macrophage-associated cytokines like tumor necrosis factor (TNF)-a and interferon (IFN)-y. Advances in understanding of the pathobioIogy of atherosclerosis have implicated inflammation as a central contributor to its initiation and progression.C-reactive protein (CRP) is the best studied of the inflammatory biomarkers in CAD and increasing evidence suggests the localization of CRP in the atherosclerotic plaque and its involvement in inflammatory process of atherosclerosis. An interesting novel biomarkers that has been extensively studied recently is soluble RAGE: its serum levels correlate positively with occurrence and severity of CAD, underlining their central role in the Pathogenesis of atherosclerosis. In recent years, many genes have been extensively explored, strong evidence of a molecular genetic association with coronary artery disease (CAD) or myocardial. In particular, in genome-wide study many loci were found to be associated with CAD. Finally, the most recent evidencesshows that miRNAs in a stable form can be detected in serum and in plasma and that they may be useful as biomarkers for CAD. However, the influence of endothelial activation and atherosclerotic disease, and that of current vasculoprotective therapy, on levels of circulating miRNAs is still unknown.The aim of the present review was to systematically report current evidence on the promising new biomarkers recently found to be associated with coronary artery disease and to evaluate their possible role in risk assessment. Drugs that inhibit inflammatory pathways are the subject of current research, but successful adoption of immunosuppressive drugs, means finding safe and effective compounds capable of directly suppressing plaque inflammation.

KW - Atherosclerosis

KW - Biomarkers

KW - Coronary artery disease

UR - http://www.scopus.com/inward/record.url?scp=84957366069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957366069&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84957366069

SN - 9781634828550

SN - 9781634828024

SP - 135

EP - 152

BT - New Developments in Myocardial Ischemia Research

PB - Nova Science Publishers, Inc.

ER -